CVS Health (CVS) Tops Q2 EPS by 10c; cuts profit guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CVS Health (CVS) PT Lowered to $63 at Deutsche Bank
August 8, 2024 12:31 PM EDTDeutsche Bank analyst George Hill lowered the price target on CVS Health (NYSE: CVS) to $63.00 (from $64.00) while maintaining a Hold rating.
The analyst comments "The Tumult Reaches a New High, as Guidance Reaches a New Low: CVS reported Q2 results and provided an updated earnings outlook with a... More
CVS Health (CVS) cuts full-year EPS guidance on continued pressure in the health care benefits unit
August 7, 2024 6:45 AM EDT(Updated - August 7, 2024 9:56 AM EDT)
CVS Health (NYSE: CVS) reported second-quarter earnings that beat analyst expectations, but shares fell by more than 2% as the company cut its full-year guidance, citing continued pressure in its Health Care Benefits segment.
The healthcare giant reported adjusted earnings per share (EPS) of $1.83 for Q2, surpassing the analyst estimate of $1.73. However, revenue came in at $91.2 billion, slightly below the consensus estimate of $91.43 billion, though it represented a 2.6% increase YoY.
CVS Health revised its full-year 2024 adjusted EPS guidance to a range of $6.40 to $6.65, down from its... More
